KR102856089B1 - Tlr8 아고니스트 - Google Patents

Tlr8 아고니스트

Info

Publication number
KR102856089B1
KR102856089B1 KR1020217011377A KR20217011377A KR102856089B1 KR 102856089 B1 KR102856089 B1 KR 102856089B1 KR 1020217011377 A KR1020217011377 A KR 1020217011377A KR 20217011377 A KR20217011377 A KR 20217011377A KR 102856089 B1 KR102856089 B1 KR 102856089B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
tlr8
acceptable salt
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217011377A
Other languages
English (en)
Korean (ko)
Other versions
KR20210060567A (ko
Inventor
저 카이
페이 쑨
찰스 제트. 딩
슈휘 첸
Original Assignee
치아타이 티안큉 파마수티컬 그룹 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치아타이 티안큉 파마수티컬 그룹 주식회사 filed Critical 치아타이 티안큉 파마수티컬 그룹 주식회사
Publication of KR20210060567A publication Critical patent/KR20210060567A/ko
Application granted granted Critical
Publication of KR102856089B1 publication Critical patent/KR102856089B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217011377A 2018-09-19 2019-09-19 Tlr8 아고니스트 Active KR102856089B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811094969.4 2018-09-19
CN201811094969 2018-09-19
PCT/CN2019/106687 WO2020057604A1 (zh) 2018-09-19 2019-09-19 Tlr8激动剂

Publications (2)

Publication Number Publication Date
KR20210060567A KR20210060567A (ko) 2021-05-26
KR102856089B1 true KR102856089B1 (ko) 2025-09-04

Family

ID=69888288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011377A Active KR102856089B1 (ko) 2018-09-19 2019-09-19 Tlr8 아고니스트

Country Status (11)

Country Link
US (1) US12054482B2 (https=)
EP (1) EP3854794B1 (https=)
JP (1) JP7498702B2 (https=)
KR (1) KR102856089B1 (https=)
CN (2) CN112805283B (https=)
AU (1) AU2019344868B2 (https=)
CA (1) CA3112953A1 (https=)
ES (1) ES2999323T3 (https=)
PH (1) PH12021550601A1 (https=)
SG (1) SG11202102641RA (https=)
WO (1) WO2020057604A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist
EP4122931B1 (en) * 2020-03-18 2025-07-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline form of tlr8 agonist
CN116472047B (zh) * 2021-11-05 2025-06-17 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
SG194852A1 (en) 2011-05-18 2013-12-30 Janssen R & D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds

Also Published As

Publication number Publication date
JP7498702B2 (ja) 2024-06-12
EP3854794A1 (en) 2021-07-28
JP2022501350A (ja) 2022-01-06
AU2019344868A1 (en) 2021-04-15
AU2019344868B2 (en) 2024-06-27
ES2999323T3 (en) 2025-02-25
US12054482B2 (en) 2024-08-06
CN112805283A (zh) 2021-05-14
WO2020057604A1 (zh) 2020-03-26
SG11202102641RA (en) 2021-04-29
PH12021550601A1 (en) 2021-11-29
CN115650979A (zh) 2023-01-31
KR20210060567A (ko) 2021-05-26
CA3112953A1 (en) 2020-03-26
US20210371414A1 (en) 2021-12-02
EP3854794A4 (en) 2022-06-15
CN112805283B (zh) 2022-09-20
EP3854794B1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
CN111225896B (zh) 免疫调节剂化合物
CN106810548B (zh) 一种二氢异喹啉类化合物
CN109311851B (zh) 二氢嘧啶基苯并氮杂䓬甲酰胺化合物
CN111225665A (zh) 大环免疫调节剂
CN114340633A (zh) 用于治疗pd-l1疾病的三芳基化合物
CA3230542A1 (en) Novel ras inhibitors
KR102856089B1 (ko) Tlr8 아고니스트
JP2019527202A (ja) 免疫調節化合物
JP2017513883A (ja) ４−アミノ−イミダゾキノリン化合物
CN114555080A (zh) 用于治疗pd-l1疾病的杂芳基联苯胺
EA034749B1 (ru) Противовирусные соединения
CN109867675A (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
WO2023036311A1 (zh) 可离子化脂质体、其制备及在基因递送中的应用
CN114206338A (zh) 作为pd-l1抑制剂的二氢化茚类
CN113614095A (zh) 作为精氨酸酶抑制剂的烷基硼酸类化合物
JP2023145644A (ja) ジヒドロイソキノリン系化合物
EP4497752A1 (en) Pyrimido-pyridazinone compound as toll-like receptor agonist
CN120548314A (zh) 含有三氟甲磺酰基的化合物
AU2019361697B2 (en) TLR8 agonist
CN115667274A (zh) 作为sting调节剂的杂环化合物
RU2800877C2 (ru) Агонист tlr8
HK40048022A (en) Tlr8 agonist
HK40048022B (en) Tlr8 agonist
TWI716427B (zh) 吡咯并[2,3-d]嘧啶化合物或其鹽
TW202515531A (zh) 兩親性ｔｌｒ７／８佐劑及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)